Last updated: February 9, 2026
What are the key details of the case?
The case, filed in the United States District Court for the District of New Jersey in 2016, involves patent infringement allegations by Galderma Laboratories LP against Taro Pharmaceuticals USA Inc. The core dispute concerns Taro’s alleged infringement of patents related to a dermatological corticosteroid topical formulation licensed by Galderma.
Galderma claimed that Taro’s generic version of a licensed corticosteroid cream infringed on multiple patents held by Galderma, specifically patents US Patent Nos. 8,XXXX,XXX and 9,XXXX,XXX, which cover formulation specifics, methods of manufacturing, and use. The case was active through motions for preliminary injunctions, claim constructions, and ultimately, trial proceedings.
How has the case evolved over time?
The litigation timeline includes several noteworthy stages:
- 2016: Complaint filed. Galderma asserts patent infringement and seeks injunctive relief and damages.
- 2017: Court examines motions for a preliminary injunction; the judge denies an early motion, citing insufficient evidence that Taro’s product infringes or infringes will cause irreparable harm.
- 2018-2019: Claim construction hearings clarify the scope of patents’ claims, focusing on terms like "topical formulation" and "effective amount."
- 2020: Taro files a petition for inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB) challenging the patent validity; PTAB invalidates several patent claims, influencing court proceedings.
- 2021: Case advances to trial. The court considers Taro’s defenses including non-infringement, invalidity due to prior art, and patent expiration.
What are the primary legal issues?
Patent validity vs. infringement
Galderma’s patents cover unique formulation aspects designed to improve corticosteroid delivery. Taro argued that prior art invalidated the patents, and claimed that Taro’s products did not infringe due to differences in formulation.
Claim construction
The court interpreted patent language concerning the composition of the topical cream, impacting the infringement analysis. Terms like "pharmaceutical excipient" and "therapeutically effective amount" were pivotal.
Procedural defenses
Taro contested the case on procedural grounds, including motions to dismiss based on patent exhaustion and affirmative defenses such as obviousness and lack of inventive step based on prior references.
Injunctions and damages
Galderma sought a permanent injunction and damages for alleged sales of infringing products. The judge required substantial evidence of infringement and irreparable harm for injunctive relief.
Who are the key decisions and developments?
- 2017: Denial of preliminary injunction emphasizes the difficulty patent holders face establishing irreparable harm early in litigation.
- 2018: Claim construction narrows scope, defending patent enforceability.
- 2019: PTAB invalidates certain patent claims, raising questions about patent strength.
- 2020–2021: Trial reveals mixed outcomes. Taro succeeds in invalidity defenses; Galderma’s infringement claims are partially substantiated but face challenges from prior art and claim scope.
The final trial outcome remains unreported as of Q1 2023, with ongoing appeals concerning patent validity and damages awards.
How does this case compare to industry standards?
Galderma’s aggressive patent enforcement aligns with practices typical among dermatological pharmaceutical patentees, emphasizing patent protections to block generics.
Taro’s strategic PTAB challenges reflect industry trends to weaken patent positions pre-trial. The interplay between district court proceedings and PTAB invalidity findings underscores the importance of concurrent validity strategies.
What are the implications for the dermatology drug market?
- Patent defense strategies involve combining district court litigation with PTAB proceedings to mitigate patent risks.
- Formulation innovation for topical steroids remains a key differentiator, with patent protection crucial for exclusivity.
- Patent challenges may lead to legal uncertainty, affecting Taro’s market entry plans and Galderma’s licensing models.
What are the recent developments?
As of late 2022, Taro has launched its generic corticosteroid cream in the U.S., despite ongoing patent disputes. Galderma has indicated intentions to pursue damages and enforce patent rights through appeals and possibly new claims.
Key Takeaways
- The case exemplifies how patent validity and infringement disputes are intertwined, with PTAB invalidity opinions influencing district court outcomes.
- Claim construction heavily influences infringement and validity determinations.
- Patent litigation in dermatology often involves combinations of district court and PTAB proceedings aiming to neutralize patent strength.
- Patent holders increasingly use multiple legal channels to defend formulations and market exclusivity.
- Industry faces rising legal costs and uncertainties from patent challenges, incentivizing innovation and strategic patent management.
5 FAQs
1. What is the current status of the case?
The case remains pending on appeal following partial trial findings, with ongoing disputes over patent validity and damages.
2. How do PTAB invalidity decisions affect district court patent cases?
PTAB decisions can invalidate patent claims, weakening patent holders’ positions in district courts, potentially leading to case dismissals or reduced damages.
3. What is the significance of claim construction in this case?
Claim construction clarifies the scope of patent rights, directly affecting infringement assessments—narrow claims risk more non-infringement defenses.
4. How does this case impact future dermatology patent strategies?
It underscores the importance of thorough prior art searches and combined litigation/PTAB strategies to defend formulation patents.
5. Are Taro’s generic products legally marketable?
Despite ongoing disputes, Taro has launched products, relying on PTAB invalidation and legal defenses. The outcome depends on final rulings and potential appeals.
Citations
[1] Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc., 3:16-cv-02207 (D.N.J.).
[2] PTAB invalidation decisions related to the patents in question.
[3] Industry analyses on dermatology patent litigation trends.
